LUNG CANCER

Alectinib shows remarkable 4-year survival rates in early-stage ALK-positive lung cancer, outperforming chemotherapy in disease-free survival and CNS recurrence.

Pembrolizumab significantly improves survival rates in early-stage non-small cell lung cancer, establishing a new standard of care in perioperative therapy.

Sacituzumab tirumotecan significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer compared to traditional chemotherapy.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

The DREAM3R trial explores durvalumab plus chemotherapy for advanced pleural mesothelioma, revealing promising survival rates despite early study limitations.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

The SKYSCRAPER-03 trial showed that consolidation tiragolumab plus atezolizumab does not improve progression-free survival in advanced lung cancer compared to durvalumab.

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

Alectinib shows promising long-term survival benefits over crizotinib in advanced ALK-positive lung cancer, highlighting significant clinical advancements.

Sevabertinib shows promising efficacy in treating HER2-mutant advanced NSCLC, achieving high response rates and durable outcomes in clinical trials.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

A recent study reveals that systematic mediastinal lymph node dissection is unnecessary for stage T1 GGO-dominant lung adenocarcinoma, enhancing patient outcomes.

New trial data shows ivonescimab combined with chemotherapy significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer patients.

New findings reveal zongertinib's effectiveness against brain metastases in HER2-mutant non–small cell lung cancer, offering hope for better treatment options.

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

Oncologists explore advanced treatment options for ROS1-positive non-small cell lung cancer, highlighting improved efficacy and personalized therapy choices.

Roy S. Herbst discusses advancements in EGFR-targeted therapies for early-stage NSCLC, highlighting improved survival rates and the role of molecular residual disease.

Innovative treatments like JAK2 inhibitors and bispecific antibodies show promise in overcoming immunotherapy resistance in non-small cell lung cancer.

During a live event, Misty D. Shields, MD, PhD, discusses how trilaciclib reduces myelosuppression and other complications in small cell lung cancer.

New data from the THIO-101 trial shows ateganosine combined with cemiplimab significantly improves progression-free survival in advanced lung cancer patients.

A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.